Table 2 Anti-angiogenesis drugs currently approved for patient use

Monoclonal anti-VEGF antibody

 Bevacizumab (Avastin)

Improved PFS in the majority of trials

No OS in the majority of trials

[216,217,218,219,220]

 Ramucirumab (Cyramza)

Improved PFS in the majority of trials

No OS in the majority of trials

[221,222,223]

Chimeric VEGF/PIGF neutralizing receptor

 Ziv-aflibercept (VEGF trap)

Improved PFS in CRC and NSCLC

Little to no OS improvement; no PFS improvement in PACA

[224,225,226]

Small-molecule VEGFR TKI

 Sorafenib (Nexavar)

Improved PFS in RCC improved OS in HCC

No OS improvement in RCC; no PFS or OS improvement in metastatic melonma or NSCLC

[225, 227, 228]

 Sunitinib (Sutent)

Improved PFS in advanced/metastatic RCC, GIST, pancreatic NETs, and PRCA; increased OS in RCC and pancreatic NETs

No OS improvement in the majority of trials, no PFS or OS improvement in metastatic BRCA or CRCA

[225, 229,230,231]

 Pazopanib (Votrient)

Improved PFS in RCC and STS

No OS improvement

[232, 233]

 Vandetanib (Caprelsa)

Improved PFS in metastatic MTC

No OS improvement; little/no PFS improvement in metastatic NSCLC

[225, 234, 235]

 Vatalanib/PTK787

–

No OS improvement; no/little PFS improvement in metastatic CRCA

[225]

 Cediranib

–

No improvement in OS or PFS

[236]

 Axitinib (Inlyta)

Improved PFS in RCC

No OS improvement; no PFS improvement in metastatic PACA

[237]

 Everolimus (Afinitor)

Improved PFS in BRCA

No OS improvement

[165,166,167]